Clinical Report: Evaluating the Advantages and Disadvantages of Glucose Monitors for Toddlers Aged Two

Overview

The FDA has approved the Dexcom Stelo, the first over-the-counter continuous glucose monitor (CGM) for children aged 2 and older. This approval may enhance access to glucose monitoring.

Background

The rise in youth-onset type 2 diabetes and obesity highlights the need for effective monitoring tools. Continuous glucose monitors provide real-time data that can help manage these conditions. However, the implications of over-the-counter access for young children remain uncertain, with mixed opinions among healthcare professionals regarding its impact.

Data Highlights

No numerical data available in the source material.

Key Findings

• The FDA cleared Dexcom's Stelo for marketing as the first OTC CGM for children aged 2 and older.
• CGMs can help track glucose levels and inform dietary and lifestyle adjustments.
• Some clinicians believe CGMs could improve health outcomes for underserved populations.

Clinical Implications

Healthcare providers should be aware of the potential benefits and risks associated with over-the-counter CGMs for young children.

Conclusion

The introduction of OTC CGMs for young children presents both opportunities for improved health monitoring.

Related Resources & Content

1. FDA, FDA, 2026 -- FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children
2. American Diabetes Association, Diabetes Care, 2026 -- Diabetes Technology: Standards of Care in Diabetes—2026
3. The Journal of Clinical Endocrinology & Metabolism — Transforming the Oral Glucose Tolerance Test: Harnessing Real-Time Data and Enhanced Insights from Continuous Glucose Monitoring
4. conexiant — FDA Expands OTC CGM Access to Children
5. The Journal of Clinical Endocrinology & Metabolism — Assessment of the Feasibility, Acceptability, and Validity of an At-Home Continuous Glucose Monitoring Oral Glucose Tolerance Test in Adolescents
6. The Journal of Clinical Endocrinology & Metabolism — Emerging Technologies in Diabetes Management: An Overview of Recent Developments
7. FDA Expands OTC CGM Access to Children
8. FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children | FDA
9. 7. Diabetes Technology: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
10. A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes - PMC